Krok-Schoen Jessica L, Fisher James L, Stephens Julie A, Mims Alice, Ayyappan Sabarish, Woyach Jennifer A, Rosko Ashley E
Division of Medical Dietetics and Health Sciences, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, Ohio.
Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Cancer Med. 2018 Jul;7(7):3425-3433. doi: 10.1002/cam4.1461. Epub 2018 Apr 13.
Evaluating population-based data of hematologic malignancies (HMs) in older adults provides prognostic information for this growing demographic. Incidence rates and one- and five-year relative survival rates were examined for specific HMs among adults ages ≥75 years using data from the Surveillance, Epidemiology and End Results (SEER) Program. Hematologic malignancy cases (Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML)) were reported to one of 18 SEER registries. Recent average annual (2010-2014) incidence rates and incidence trends from 1973 to 2014 were examined for cases ages ≥75 years. One- and five-year relative cancer survival rates were examined for adults ages ≥75 years diagnosed 2007-2013, with follow-up into 2014. From 1973 to 2014, incidence rates increased for NHL, MM, and AML, decreased for HL, and remained relatively stable for ALL, CLL, and CML among adults ages ≥75 years. The highest one- and five-year relative survival rates were observed among adults with CLL ages 75-84 years (1 year: 91.8% (95% CI = 91.8-90.8)) and 5 years: 76.5% (95% CI = 74.2-78.6)). The lowest one- and five-year survival rates were observed among adults with AML ages 75-84 (1 year: 18.2% (95% CI = 74.2-78.6) and 5 years: 2.7% (95% CI = 2.0-3.6)). Survival for older adults ages ≥75 years with HMs is poor, particularly for acute leukemia. Understanding the heterogeneity in HM outcomes among older patients may help clinicians better address the hematological cancer burden and mortality in the aging population.
评估老年人群血液系统恶性肿瘤（HMs）的基于人群的数据可为这一不断增长的人口群体提供预后信息。利用监测、流行病学和最终结果（SEER）计划的数据，对年龄≥75岁的成年人中特定HMs的发病率以及1年和5年相对生存率进行了研究。血液系统恶性肿瘤病例（霍奇金淋巴瘤（HL）、非霍奇金淋巴瘤（NHL）、多发性骨髓瘤（MM）、急性淋巴细胞白血病（ALL）、慢性淋巴细胞白血病（CLL）、急性髓系白血病（AML）和慢性髓系白血病（CML））被报告给18个SEER登记处之一。研究了年龄≥75岁病例的近期年均（2010 - 2014年）发病率以及1973年至2014年的发病趋势。对2007 - 2013年诊断且随访至2014年的年龄≥75岁成年人的1年和5年相对癌症生存率进行了研究。1973年至2014年，年龄≥75岁的成年人中，NHL、MM和AML的发病率上升，HL的发病率下降，ALL、CLL和CML的发病率相对稳定。在75 - 84岁的CLL成年人中观察到最高的1年和5年相对生存率（1年：91.8%（95%CI = 91.8 - 90.8））和5年：76.5%（95%CI = 74.2 - 78.6））。在75 - 84岁的AML成年人中观察到最低的1年和5年生存率（1年：18.2%（95%CI = 74.2 - 78.6）和5年：2.7%（95%CI = 2.0 - 3.6））。年龄≥75岁的老年HMs患者的生存率较差，尤其是急性白血病患者。了解老年患者中HM结局的异质性可能有助于临床医生更好地应对老年人群中的血液系统癌症负担和死亡率。
